Article
Urology & Nephrology
Furkan Dursun, Chen-Pin Wang, Daniel MacCarthy, Ahmed M. Mansour, Deepak K. Pruthi, Dharam Kaushik, Ian M. Thompson, Michael A. Liss
Summary: The purpose of this study was to determine if the absolute PSA value after 6 months of ADT is predictive of survival in patients with prostate adenocarcinoma. The results showed that patients with high and intermediate PSA values had a higher risk of PCSM and all-cause mortality compared to those with low PSA values. This measure can be used to rapidly assess the efficacy of new interventions in clinical trials.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
K. Stinesen Kollberg, E. Holmberg, A. Josefsson, J. Hugosson, R. Arnsrud Godtman
Summary: The aim of this study was to describe the level of pre-testing and contamination in the Goteborg-1 prostate cancer screening trial. The results showed that similar proportions of men were prostate specific antigen-tested in both the screening group and control group, yet only a minority of contamination prostate specific antigens led to biopsy. Organized screening was found to be more effective in reducing prostate cancer mortality than non-organized testing.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Maha Hussain, Cora N. Sternberg, Eleni Efstathiou, Karim Fizazi, Qi Shen, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Ugo De Giorgi, Neal D. Shore, Fred Saad
Summary: This study analyzed the relationship between depth of PSA decline and clinical outcomes in men with nonmetastatic castration-resistant prostate cancer. The results showed that greater depth of PSA decline was associated with improved metastasis-free survival and overall survival, suggesting a previously underestimated relationship between changes in PSA levels and clinical outcomes.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Patrick-Julien Treacy, Ugo G. Falagario, Francois Magniez, Parita Ratnani, Ethan Wajswol, Alberto Martini, Ivan Jambor, Peter Wiklund, Imad Bentellis, Flora Barthe, Natasha Kyprianou, Matthieu Durand, Daniel Steffens, Sascha Karunaratne, Scott Leslie, Ruban Thanigasalam, Ash Tewari
Summary: This study aimed to evaluate the genomic risk of patients with persistent prostate specific antigen (PSA) using mRNA expression analysis and a validated prognostic genomic-risk classifier. The findings revealed unique genomic features of patients with persistent PSA and confirmed that this condition is associated with a worse prognosis.
MINERVA UROLOGY AND NEPHROLOGY
(2023)
Article
Urology & Nephrology
Sebastiaan Remmers, Chris H. Bangma, Rebecka A. Godtman, Sigrid. Carlsson, Anssi Auvinen, Teuvo L. J. Tammela, Louis J. Denis, Vera Nelen, Arnauld Villers, Xavier Rebillard, Maciej Kwiatkowski, Franz Recker, Stephen Wyler, Marco Zappa, Donella Puliti, Giuseppe Gorini, Alvaro Paez, Marcos Lujan, Daan Nieboer, Fritz H. Schroeder, Monique J. Roobol
Summary: Based on the guidelines of the European Association of Urology, a risk-based strategy for prostate cancer screening should be determined by the first prostate-specific antigen (PSA) level and age. In this study, the baseline PSA level was found to guide decisions on the repeat screening interval and had an impact on prostate cancer detection and specific mortality rates.
Article
Oncology
Aurore Carrot, Reza-Thierry Elaidi, Olivier Colomban, Denis Maillet, Michel Tod, Benoit You, Stephane Oudard
Summary: This study analyzed a phase III trial dataset in metastatic prostate cancer patients, demonstrating the significant prognostic value of modeled PSA kinetics parameters assessed using mathematical modeling. The results suggest that these parameters could serve as early prognostic/predictive factors in patients undergoing systemic treatments.
Article
Andrology
Jeong Hoon Oh, Ho Seok Chung, Myung Soo Kim, Eu Chang Hwang, Seung Il Jung, Dongdeuk Kwon, Kwangsung Park
Summary: PSA parameters have a similar diagnostic value in predicting prostate cancer in men with gray-zone PSA levels regardless of testosterone levels.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2022)
Article
Urology & Nephrology
Ivo I. de Vos, Annick Meertens, Renee Hogenhout, Sebastiaan Remmers, Monique J. Roobol
Summary: This study concludes that PSA-based screening for prostate cancer can reduce metastasis and mortality. The longer the follow-up, the greater the reduction in deaths and metastasis. The study also suggests that starting screening between the ages of 70 and 74 is not effective and repeated screenings are necessary.
Article
Urology & Nephrology
Kendrick Yim, Chaoran Ma, Sigrid Carlsson, Hans Lilja, Lorelei Mucci, Kathryn Penney, Adam S. Kibel, Scott Eggener, Mark A. Preston
Summary: Adding percent free PSA to total PSA improved prediction of clinically significant prostate cancer and fatal prostate cancer. Free PSA can be used to stratify risk in screening and reduce unnecessary prostate biopsies.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Tarik Benidir, Ethan Austhof, Ryan D. D. Ward, Justin Ream, Jenifer Bullen, Baris Turkbey, Peter A. A. Pinto, Francesco Giganti, Eric A. A. Klein, Andrei S. S. Purysko
Summary: The study aimed to evaluate the impact of UroLift on prostate magnetic resonance imaging (MRI) quality. The results showed that UroLift has a negative impact on MRI quality, particularly in the mid-basal region, obscuring a significant portion of the prostate on diffusion-weighted images.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Michael S. Leapman, Kimberly Stone, Roxanne Wadia, Lesley S. Park, Cynthia L. Gibert, Matthew B. Goetz, Roger Bedimo, Maria Rodriguez-Barradas, Fatma Shebl, Amy C. Justice, Sheldon T. Brown, Kristina Crothers, Keith M. Sigel
Summary: The risk of prostate cancer among individuals living with human immunodeficiency virus (HIV) is not well understood. This study found that when accounting for less prostate-specific antigen (PSA) testing among HIV-positive individuals, the incidence of prostate cancer was similar to that of HIV-negative individuals.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Francesco Claps, Nicola Pavan, Paolo Umari, Michele Rizzo, Fabio Barbone, Manuela Giangreco, Giovanni Liguori, Carmen M. Mir, Rossana Bussani, Carlo Trombetta
Summary: The study found that incidental prostate cancer (iPCa) is common in patients undergoing radical cystectomy (RC) for bladder cancer, with most cases being organ-confined and well differentiated. Regardless of clinical relevance, iPCa does not impact survival outcomes as bladder cancer drives the prognosis of these patients.
MINERVA UROLOGY AND NEPHROLOGY
(2021)
Article
Oncology
Daniel J. Herr, David A. Elliott, Gillian Duchesne, Kristian D. Stensland, Megan E. V. Caram, Christina Chapman, Jennifer A. Burns, Brent K. Hollenbeck, Jordan B. Sparks, Chris Shin, Alexander Zaslavsky, Alexander Tsodikov, Ted A. Skolarus
Summary: This study aims to examine the 10-year clinical outcomes of patients with localized prostate cancer undergoing radiation therapy within a national healthcare system. The results showed improved survival rates for high-risk disease, providing important benchmarks for clinical decision-making.
Article
Multidisciplinary Sciences
Libin Nan, Kai Guo, Mingmin Li, Qi Wu, Shaojun Huo
Summary: A nomogram prediction model for prostate cancer was developed using clinical data, and compared with other prediction models. The results showed that the model had higher predictive value, and could be used to assess the probability of prostate cancer and guide prostate biopsy.
Article
Urology & Nephrology
John R. Bright, Rosina T. Lis, Anson T. Ku, Nicholas T. Terrigino, Nichelle C. Whitlock, Shana Y. Trostel, Nicole Carrabba, Stephanie A. Harmon, Baris Turkbey, Scott Wilkinson, Adam G. Sowalsky
Summary: The study evaluated the ability of antibodies against PSMA to specifically detect residual tumor in patients treated with iADT and enzalutamide. The results showed that PSMA reacted positively with tumor in all cases and had high sensitivity but low specificity for benign regions. PSMA could also identify highly dedifferentiated prostate carcinomas, indicating its potential as a valuable marker.
JOURNAL OF UROLOGY
(2022)